Ocriplasmin
- Generic Name
- Ocriplasmin
- Brand Names
- Jetrea
- Drug Type
- Biotech
- CAS Number
- 1048016-09-6
- Unique Ingredient Identifier
- 7V6HE3DM5A
- Background
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.
- Indication
Ocriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
- Associated Conditions
- Symptomatic Vitreomacular Adhesion (VMA)
EMA's CHMP Recommends Approval of Novartis' Jetrea for Vitreomacular Traction Treatment
• Novartis' eye care division Alcon receives positive CHMP opinion for Jetrea (ocriplasmin) to treat vitreomacular traction and associated macular holes in European patients.
• The innovative treatment addresses an unmet need for 250,000-300,000 European patients with VMT, offering an alternative to the current 'watchful waiting' approach before late-stage surgery.
• Following FDA approval in October 2012, Europe is set to become the first region outside the US to approve Jetrea, marking a significant advancement in retinal therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath